Ovchinnikov A Iu, Dzhenzhera G E, Lopatin A S
Vestn Otorinolaringol. 2009(5):59-62.
The objective of this study was to evaluate clinical efficiency and safety of combined therapy including systemic antibiotics, decongestants, and sinuforte in patients with acute suppurative bacterial rhinosinusitis. The patients allocated to two groups comprising 25 subjects each were treated for a total of 8 days. Those in the study group received sinuforte once daily, 10.0 g of amoxilav twice daily, and xylometazole (BID). Control patients were given only amoxilav and xylometazole at the same doses. Dynamics of subjective and objective signs of rhinosinusitis, the mucociliary transport rate, and tolerance of sinuforte were the main variables assessed in this study. The introduction of sinuforte into combined therapy was shown to significantly improve dynamics of subjective and objective signs of rhinosinusitis compared with control. Results of the treatment with sinuforte are described as excellent in 19 patients against 13 in the control group, as good in 4 and 9 patients and satisfactory in 3 and 2 ones respectively. None of the patients needed puncture of maxillary sinuses in the course of the treatment. The mucociliary transport time prior to therapy was estimated at 22.18+/-3.82 and 22.36+/-3.64 in the study and control groups respectively (the difference was insignificant at p>0.05) compared with 14.88+/-3.12 and 16.02+/-3.98 min (p<0.01) on day 8 after the initiation of therapy. The tolerance of sinuforte was estimated at 5.64 based on the 10-score visual-analogous scale. Results of the study confirm that treatment with sinuforte combined with antibiotics (amoxicillin and clavulante) is a safe and efficacious therapeutic modality for the patients with acute bacterial rhinosinusitis.
本研究的目的是评估全身用抗生素、减充血剂和仙露贝联合治疗急性化脓性细菌性鼻窦炎患者的临床疗效和安全性。将患者分为两组，每组25例，共治疗8天。研究组患者每天服用一次仙露贝，每天两次服用10.0 g阿莫西林克拉维酸，以及赛洛唑啉（每日两次）。对照组患者仅给予相同剂量的阿莫西林克拉维酸和赛洛唑啉。鼻窦炎主观和客观体征的动态变化、黏液纤毛传输速率以及仙露贝的耐受性是本研究评估的主要变量。与对照组相比，联合治疗中加入仙露贝可显著改善鼻窦炎主观和客观体征的动态变化。仙露贝治疗结果显示，19例患者为优，而对照组为13例；4例和9例患者为良，3例和2例患者为满意。治疗过程中无一例患者需要进行上颌窦穿刺。治疗前研究组和对照组的黏液纤毛传输时间分别估计为22.18±3.82和22.36±3.64（p>0.05时差异不显著），而治疗开始后第8天分别为14.88±3.12和16.02±3.98分钟（p<0.01）。根据10分视觉模拟量表，仙露贝的耐受性估计为5.64。研究结果证实，仙露贝联合抗生素（阿莫西林和克拉维酸）治疗对急性细菌性鼻窦炎患者是一种安全有效的治疗方式。
